Biocon And Civica Prepare For Low-Priced Insulin Glargine Launch In US

Private-Label Lantus Biosimilar Will Be Available At $11 Per Pen

 
• By Dave Wallace
  
Biocon and Civica are preparing for a January 2026 launch (Shutterstock)

More from Deals

More from Policy & Regulation